Accretion Nutraveda Ltd
Accretion Nutraveda Ltd (ANL) last reported results for the quarter ended Mar 2026, with sales of ₹19.54 crore and net profit of ₹2.69 crore. The stock last traded at ₹305, a market capitalisation of ₹221 crore, on a P/E of 43.6. Over the past 52 weeks the stock has ranged between ₹150 and ₹313. Figures are as of 6 Oct 2026 and are not real time.
Accretion Nutraveda Ltd share price and key metrics
- Current price
- ₹305
- Market cap
- ₹221 cr
- Stock P/E
- 43.6
- Book value
- ₹49
- ROE
- 25.0%
- ROCE
- 27.7%
- Dividend yield
- 0.00%
- 52w high / low
- 313/150
Metrics as of 6 Oct 2026. Not real time.
Track Accretion Nutraveda Ltd
Cruxal reads every Accretion Nutraveda Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Accretion Nutraveda Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 127%
- TTM
- 110%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 163%
- TTM
- 103%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 35%
- Last Year
- 25%
Accretion Nutraveda Ltd quarterly results
| ₹ crore | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 10.85 | 14.06 | 19.54 |
| Expenses | 8.27 | 10.76 | 15.98 |
| Operating profit | 2.58 | 3.3 | 3.56 |
| OPM % | 23.78% | 23.47% | 18.22% |
| Other income | -0 | -0 | 0.11 |
| Interest | 0.26 | 0.26 | 0.27 |
| Depreciation | 0.11 | 0.17 | 0.1 |
| Profit before tax | 2.21 | 2.87 | 3.3 |
| Tax % | 22.17% | 18.47% | 18.48% |
| Net profit | 1.72 | 2.33 | 2.69 |
| EPS (₹) | 35.32 | 4.38 | 3.72 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Accretion Nutraveda Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 2.89 | 5.01 | 16 | 33.59 |
| Operating profit | 0.62 | 1.23 | 3.71 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% |
| Net profit | 0.28 | 0.82 | 2.5 | 5.07 |
| EPS (₹) | 7.78 | 22.78 | 51.33 | 7.00 |
TTM is the trailing twelve months to the most recent quarter.
Accretion Nutraveda Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.10 | 0.72 | 4.56 | 28.23 |
| Borrowings | 1.97 | 2.17 | 3.86 | 4.23 |
| Other liabilities | 1.83 | 1.39 | 1.63 | 2.08 |
| Total liabilities | 4.06 | 4.64 | 10.54 | 41.78 |
| Fixed assets | 1.49 | 1.28 | 1.83 | 1.66 |
| CWIP | -0.00 | 0.10 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 |
| Other assets | 2.57 | 3.26 | 8.71 | 40.12 |
| Total assets | 4.06 | 4.64 | 10.54 | 41.78 |
As reported by the company. Total assets equal total liabilities by construction.
Accretion Nutraveda Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 0.68 | 0.23 | -2.22 | -9.42 |
| Cash from investing | -0.01 | -0.16 | -0.87 | -14.50 |
| Cash from financing | -0.63 | -0.04 | 2.98 | 25.19 |
| Net cash flow | 0.04 | 0.03 | -0.10 | 1.26 |
| Free cash flow | 0.67 | 0.07 | -3.09 | -15.45 |
| CFO / operating profit | 110% | 27% | -42% | -113% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Accretion Nutraveda Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 42.34% | 57.57% | 27.73% |
| Debtor days | 101.04 | 18.21 | 74.60 | 88.13 |
| Inventory days | 279.12 | 303.74 | 158.50 | 136.10 |
| Days payable | 354.26 | 113.58 | 30.73 | 11.35 |
| Cash conversion cycle | 25.89 | 208.37 | 202.36 | 212.87 |
| Working capital days | 8.84 | 7.29 | 128.89 | 195.59 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Accretion Nutraveda Ltd shareholding pattern
Promoters held 73.48% at Jun 2026, broadly unchanged since Mar 2026. FIIs 1.08% and DIIs 6.10%.
| % held | Mar 2026 | Jun 2026 |
|---|---|---|
| Promoters | 73.48% | 73.48% |
| FIIs | 1.08% | 1.08% |
| DIIs | 7.00% | 6.10% |
| Public | 18.43% | 19.34% |
| No. of shareholders | 427 | 396 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Accretion Nutraveda Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed herewith intimation under Regulation 74(5) of SEBI (DP) Regulation…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed herewith intimation w.r.t Closure of Trading Window
Read the full analysis - Accretion Nutraveda Ltd completes dispatch of Postal Ballot NoticeCompany Updatelow impact
Cruxal's analysis: Accretion Nutraveda Ltd has completed the dispatch of the Postal Ballot Notice to its…
Read the full analysis - Accretion Nutraveda Limited Seeks Shareholder Approval for Significant Expansion of Borrowing and Investment LimitsAGM/EGMmedium impact
Cruxal's analysis: Accretion Nutraveda Limited has issued a Postal Ballot notice seeking shareholder…
Read the full analysis - Accretion Nutraveda Limited Seeks Shareholder Approval for Significant Expansion of Business Objects and Enhanced Borrowing PowersCompany Updatemedium impact
Cruxal's analysis: Accretion Nutraveda Limited has announced a board-approved proposal to significantly…
Read the full analysis - Accretion Nutraveda Limited Seeks Shareholder Approval for Enhanced Borrowing Limits and Broadened Business ObjectsCompany Updatemedium impact
Cruxal's analysis: Accretion Nutraveda Limited has announced a board-approved proposal to significantly…
Read the full analysis - Accretion Nutraveda Ltd announces alteration of Memorandum of AssociationCompany Updatelow impact
Cruxal's analysis: Accretion Nutraveda Ltd has filed an intimation regarding the alteration of its…
Read the full analysis - Accretion Nutraveda Limited Announces Successful Conclusion of 5th Annual General Meeting and Approval of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Accretion Nutraveda Limited has successfully concluded its 5th Annual General Meeting…
Read the full analysis - Accretion Nutraveda Limited Concludes 5th Annual General Meeting; Focuses on Board Appointments and Remuneration RevisionsAGM/EGMlow impact
Cruxal's analysis: Accretion Nutraveda Limited has successfully concluded its 5th Annual General Meeting…
Read the full analysis - Accretion Nutraveda Ltd releases web link for Annual Report 2025-26Company Updatelow impact
Cruxal's analysis: Accretion Nutraveda Ltd has filed a disclosure under Regulation 30 of the SEBI Listing…
Read the full analysis - Accretion Nutraveda Ltd announces 05th Annual General Meeting and E-voting scheduleCompany Updatelow impact
Cruxal's analysis: Accretion Nutraveda Ltd has published a newspaper advertisement regarding the convening…
Read the full analysis - Accretion Nutraveda Limited Announces 5th AGM and Proposes Remuneration Revisions for Key Management PersonnelAGM/EGMlow impact
Cruxal's analysis: Accretion Nutraveda Limited has scheduled its 5th Annual General Meeting for 27 August…
Read the full analysis - Accretion Nutraveda Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Accretion Nutraveda Ltd has filed its Annual Report for the financial year 2025-26. This…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.